Prognostic role of ST2 biomarker in the development of adverse cardiovascular events in patients with new-onset coronavirus infection

Kanaeva T.V., Karoli N.A.

ABSTRACT

The aim of the study is to determine the prognostic significance of established and novel cardiovascular biomarkers (growth stimulation expressed gene 2 (ST2)) for assessing the risk of adverse cardiovascular events (ACVE) in patients with novel coronavirus infection (COVID-19) during long-term follow-up.

Methods. A non-randomized, prospective comparative study included 112 patients hospitalized with a confirmed diagnosis of COVID-19. In addition to standard laboratory tests, the levels of cardiovascular biomarkers (lactate dehydrogenase (LDH), high-sensitivity troponin I (hsTrI), high-sensitivity troponin T (hsTrT), creatine phosphokinase (CPK), creatine phosphokinase MB fraction (CPKMB), ST2) were determined on the day of hospital admission. Patients were followed for 366 [365; 380] days.

Results. During the follow-up period, 14 (12.5%) patients developed ACVE, including 4 (3.6%) deaths from cardiovascular causes. The group of patients with developed ACVE had higher admission BMI, IL-6, D-dimer, LDH, CPK, CPK-MB and ST2 concentrations (p 36 ng/mL (OR 1.23, 95% CI 1.11–1.37; AUC 0.949, sensitivity 92.9%, specificity 33%, p=0.000).

Conclusion. The ST2 level of >36 ng/mL  on the day of hospitalization as well as the presence of AH and obesity increased the likelihood of developing ACVE within 1 year of discharge in patients who had a coronavirus infection.

Keywords: ST2, cardiovascular diseases, adverse cardiovascular events, COVID-19.

For citation:

Kanaeva T.V., Karoli N.A.  Prognostic role of ST2 biomarker in the development of adverse cardio-vascular events in patients with new-onset coronavirus infection. International Journal of Heart and Vascular Diseases. 2024. 12(42): 14–20. DOI: 10.24412/2311-1623-2024-42-16-23